Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine

被引：4
|
作者：
Tomova, A.
Brodowicz, T.
Tzekova, V.
Timcheva, C.
Wiltschke, C.
Gerges, D. A.
Pawlega, J.
Spanik, S.
Inbar, M. J.
Zielinski, C. C.
机构：
[1] Plovdiv Canc Ctr, Plovdiv, Bulgaria
[2] Univ Vienna, Dept Med 1, Vienna, Austria
[3] Univ Hosp, Sofia, Bulgaria
[4] SBALO Natl Oncol Ctr, Sofia, Bulgaria
[5] Rizk Hosp, Beirut, Lebanon
[6] Klin Onkol CmuJ, Krakow, Poland
[7] Onkol Ustav Sv Alzbety, Bratislava, Slovakia
[8] Sourasky Med Ctr, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1106
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
    Liu, Zhiyong
    Wang, Xin
    Wang, Jiaqiang
    Zhang, Peng
    Li, Chao
    Wang, Bangmin
    Liu, Guancong
    Yao, Weitao
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Docetaxel/gemcitabine/toripalimabVarious toxicities
    Reactions Weekly, 2024, 1995 (1) : 73 - 73
  • [23] Docetaxel/gemcitabine/nivolumabLack of efficacy
    Reactions Weekly, 2024, 2014 (1) : 240 - 240
  • [24] A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer
    Artz, A
    Stadler, WM
    Vogelzang, NJ
    Zimmerman, T
    Ryan, C
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02): : 109 - 113
  • [25] Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
    Seidman, A. D.
    Brufsky, A.
    Ansari, R. H.
    Hart, L. L.
    Stein, R. S.
    Schwartzberg, L. S.
    Stewart, J. F.
    Russell, C. A.
    Chen, S. -C.
    Fein, L. E.
    Vargas, J. A. De La Cruz
    Kim, S. -B.
    Cavalheiro, J.
    Zhao, L.
    Gill, J. F.
    Obasaju, C. K.
    Orlando, M.
    Tai, D. F.
    ANNALS OF ONCOLOGY, 2011, 22 (05) : 1094 - 1101
  • [26] Sequential chemotherapy with gemcitabine plus carboplatin, followed by additional docetaxel for aged patients with advanced upper-tract urothelial cancer.
    Yoneyama, Takahiro
    Tobisawa, Yuki
    Yoneyama, Tohru
    Yamamoto, Hayato
    Imai, Atsushi
    Mori, Kazuyuki
    Hatakeyama, Shingo
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [27] A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma
    Cho, May
    Wang-Gillam, Andrea
    Myerson, Robert
    Gao, Feng
    Strasberg, Steven
    Picus, Joel
    Sorscher, Steven
    Fournier, Chloe
    Nagaraj, Gayathri
    Parikh, Parag
    Suresh, Rama
    Linehan, David
    Tan, Benjamin R.
    HPB, 2015, 17 (07) : 587 - 593
  • [28] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [29] Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial
    Binder, Daniel
    Beinert, Thomas
    Schweisfurth, Hans
    Grah, Christian
    Temmestfeld-Wollbrueck, Bettina
    Schaeper, Christoph
    Mueller-Hagen, Gerit
    Schuermann, Dirk
    Suttorp, Norbert
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [30] SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
    P A Vasey
    R Atkinson
    R Osborne
    D Parkin
    R Symonds
    J Paul
    L Lewsley
    R Coleman
    N S Reed
    S Kaye
    G J S Rustin
    British Journal of Cancer, 2006, 94 : 62 - 68
12345